重庆医学2018，Vol.47Issue(2)：186-188,192,4.DOI:10.3969/j.issn.1671-8348.2018.02.013
复方新诺明联合二线药物治疗耐多药结核病的临床疗效分析
Clinical efficacy of compound sulfamethoxazole combined with second-line drugs in treatment of MDR-TB
摘要
Abstract
Objective To investigate the effect of compound sulfamethoxazole(SMZ.Co) combined with second-line drugs in the treatment of multiple drug-resistant tuberculosis(MDR-TB).Methods Eighty-five cases of MDR-TB collected in this hospital from March 2014 to December 2016 were divided into the group A,B and C group.The C group underwent the conventional secondline anti-TB treatment,on this basis the group A and B were additionally added with 0.96 g and 0.48 g SMZ.Co respectively.The clinical curative effects(such as cough,phlegm,sputum bacterial negative conversion rate and X-rays) were compared among the three groups.Results Compared with C group,the cough and phlegm rates after continuous treatment for six months in the group A and B treated by combined use of SMZ.Co were significantly decreased,the difference was statistically significant(P＜0.05),while the sputum bacterial negative conversion rate,change of lesion focus and cavity,and treatment outcome rate had no statistical difference(P＞0.05).Conclusion The application of SMZ.Co combined with second-line drugs in the treatment of MDR-TB could effectively relieve the symptom of cough and phlegm.关键词
广泛耐药结核/抗结核药/复方新诺明Key words
extensively drug-resistant tuberculosis/antitubercular agents/SMZ.Co分类
医药卫生引用本文复制引用
曹培明,严晓峰,沈明..复方新诺明联合二线药物治疗耐多药结核病的临床疗效分析[J].重庆医学,2018,47(2):186-188,192,4.基金项目
重庆市卫生局重点项目(2013-1-044). （2013-1-044）
